SCHEMBL718670

SCHEMBL718670

COc1ccc(-n2cc(C(O)C3CCCCC3)c(CN3CCOCC3)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.43
CYP2D6 P10635 1/20 0.43
ALDH1A1 P00352 6/20 0.41
KDM4E B2RXH2 4/20 0.41
HTT P42858 1/20 0.41
KDM5B Q9UGL1 3/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HIF1A Q16665 1/20 0.38
EPAS1 Q99814 1/20 0.38
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
LMNA P02545 1/20 0.37
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36
GAA P10253 2/20 0.36
F10 P00742 1/20 0.36
KDM4A O75164 1/20 0.36
KDM5A P29375 1/20 0.36
KDM5C P41229 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL721464 0.84 KDM4E (0.42) SMN1; SMN2ALDH1A1KDM4EHTTMEN1
SCHEMBL716549 0.83 RAB9A (0.40) SMN1; SMN2ALDH1A1KDM4EHTTMEN1
SCHEMBL720503 0.78 IDO1 (0.42) SMN1; SMN2ALDH1A1KDM4EHTTMEN1
SCHEMBL718340 0.76 IDO1 (0.41) SMN1; SMN2ALDH1A1KDM4EHTTMEN1
SCHEMBL718287 0.76 IDO1 (0.41) SMN1; SMN2ALDH1A1KDM4EHTTMEN1
SCHEMBL716807 0.76 SMN1; SMN2 (0.51) SMN1; SMN2CYP2D6ALDH1A1KDM4EHTT
SCHEMBL716584 0.76 HIF1A (0.40) ALDH1A1KDM4EKDM5BMEN1KMT2A
SCHEMBL719884 0.74 KDM5B (0.55) SMN1; SMN2ALDH1A1KDM4EKDM5BMEN1
SCHEMBL724099 0.73 SMN1; SMN2 (0.50) SMN1; SMN2CYP2D6ALDH1A1KDM4EKDM5B
SCHEMBL719334 0.73 BCHE (0.40) SMN1; SMN2ALDH1A1KDM4EHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP SMN1; SMN2 1051/4885CYP2D6 639/4885ALDH1A1 504/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP SMN1; SMN2 1051/4885CYP2D6 639/4885ALDH1A1 504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.